GlassScriptPhysician profile
Kimberley Ryan
NPI 1306040142
$398.49
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $156.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $178.66 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $46.35 | 2022 | |
| Sunovion Pharmaceuticals INC. | $43.32 | 2021 | |
| Lilly USA, LLC | $33.98 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $25.17 | 2021 | |
| Amarin Pharma, INC. | $22.19 | 2022 | |
| Dexcom, INC. | $17.63 | 2021 | |
| Abbvie INC. | $15.66 | 2021 | |
| Pfizer INC. | $15.53 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberley Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.